Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections

Jordan R Smith, Karrine D Roberts, Michael J Rybak, Jordan R Smith, Karrine D Roberts, Michael J Rybak

Abstract

Dalbavancin is a lipoglycopeptide antibiotic recently approved by the United States Food and Drug Administration (FDA) for acute bacterial skin and skin structure infections (ABSSSIs). It is active against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and minimum inhibitory concentrations (MICs) are consistently <0.125 µg/ml, much lower than most other anti-MRSA agents. Dalbavancin possesses an extended half-life of over 1 week, allowing an initial dose of 1000 mg followed by 500 mg 1 week later to complete a course of therapy for ABSSSI. It is approximately 95% protein bound and is widely distributed throughout the body, achieving concentrations similar to plasma levels in numerous tissues. Against MRSA, dalbavancin is 4-8 times more potent than vancomycin in vitro, and limited data suggest it possesses activity against MRSA with reduced susceptibility to vancomycin such as hVISA and VISA. Dalbavancin also possesses in vitro activity against streptococci and enterococci, although activity against vancomycin-resistant enterococci is lacking. In phase 3 ABSSSI studies, dalbavancin demonstrated similar activity to vancomycin and provides a more convenient dosing regimen. Limited phase 2 data suggest dalbavancin also possesses activity in catheter-related bloodstream infections. Potential further therapeutic uses include conditions that require long-term treatment such as osteomyelitis and infective endocarditis, although data are currently lacking. The extended half-life of dalbavancin, along with its in vitro activity against gram-positive organisms with reduced susceptibility to other anti-MRSA antibiotics, suggest it could have an exciting clinical role going forward.

Keywords: Antibiotic; Dalbavancin; Lipoglycopeptide; Skin infections.

Figures

Fig. 1
Fig. 1
Chemical structure of dalbavancin

References

    1. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013;34:1–14. doi: 10.1086/668770.
    1. Moellering RC., Jr Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(Suppl 1):S3–S4. doi: 10.1086/491708.
    1. Sader HS, Farrell DJ, Flamm RK, Jones RN. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13) J Antimicrob Chemother. 2015;70(7):2053–2056.
    1. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med. 1998;104:7S–10S. doi: 10.1016/S0002-9343(98)00149-1.
    1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135–136. doi: 10.1093/jac/40.1.135.
    1. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66:82–98. doi: 10.2146/ajhp080434.
    1. Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs. 2007;16:717–733. doi: 10.1517/13543784.16.5.717.
    1. Dalvance (dalbavancin) for injection [package insert]. Chicago, IL: Durata; Rev 05/14.
    1. Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW, Mendes RE. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis. 2015;82(1):73–77. doi: 10.1016/j.diagmicrobio.2015.01.017.
    1. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–2179. doi: 10.1056/NEJMoa1310480.
    1. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(Suppl 2):ii15–ii20.
    1. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70:859–886. doi: 10.2165/11534440-000000000-00000.
    1. Nagarajan R. Structure–activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot. 1993;46:1181–1195. doi: 10.7164/antibiotics.46.1181.
    1. Trevino J, Bayon C, Arda A, et al. New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy. Chemistry. 2014;20:7363–7372. doi: 10.1002/chem.201303310.
    1. Jones RN, Flamm RK, Sader HS. Surveillance of dalbavancin potency and spectrum in the United States (2012) Diagn Microbiol Infect Dis. 2013;76:122–123. doi: 10.1016/j.diagmicrobio.2013.01.003.
    1. Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011) Diagn Microbiol Infect Dis. 2013;75:304–307. doi: 10.1016/j.diagmicrobio.2012.11.024.
    1. Chong YP, Park SJ, Kim HS, et al. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC. Diagn Microbiol Infect Dis. 2012;73:264–266. doi: 10.1016/j.diagmicrobio.2012.01.015.
    1. Citron DM, Tyrrell KL, Goldstein EJ. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. Diagn Microbiol Infect Dis. 2014;79:438–440. doi: 10.1016/j.diagmicrobio.2014.05.014.
    1. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23:99–139. doi: 10.1128/CMR.00042-09.
    1. Howden BP, Peleg AY, Stinear TP. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect Genet Evol. 2013;21:575–582. doi: 10.1016/j.meegid.2013.03.047.
    1. Ortwine JK, Werth BJ, Sakoulas G, Rybak MJ. Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the “seesaw effect”: taking advantage of the back door left open? Drug Resist Updates: Rev Comment Antimicrob Anticancer Chemother. 2013;16:73–79. doi: 10.1016/j.drup.2013.10.002.
    1. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin Infect Dis. 2008;46:668–674. doi: 10.1086/527392.
    1. Rossi F, Diaz L, Wollam A, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med. 2014;370:1524–1531. doi: 10.1056/NEJMoa1303359.
    1. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58:163–170. doi: 10.1016/j.diagmicrobio.2006.12.022.
    1. McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW. In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a Global Surveillance Program. ntimicrob Agents Chemother. 2015;59(8):5007–5009. doi: 10.1128/AAC.00274-15.
    1. Jones RN, Stilwell MG. Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains) Diagn Microbiol Infect Dis. 2013;76:239–240. doi: 10.1016/j.diagmicrobio.2013.01.002.
    1. Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis. 2011;69:342–347. doi: 10.1016/j.diagmicrobio.2010.10.031.
    1. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:940–945. doi: 10.1128/AAC.48.3.940-945.2004.
    1. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005;55(Suppl 2):ii25–ii30.
    1. Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49:465–476. doi: 10.1177/0091270008330162.
    1. Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol. 2008;48:1063–1068. doi: 10.1177/0091270008321273.
    1. Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005;45:1279–1287. doi: 10.1177/0091270005280378.
    1. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37:1298–1303. doi: 10.1086/379015.
    1. Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother. 2005;55(Suppl 2):ii31–ii35.
    1. Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007;60:681–684. doi: 10.1093/jac/dkm263.
    1. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51:1633–1642. doi: 10.1128/AAC.01264-06.
    1. Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol. 2014;41:437–443. doi: 10.1111/1440-1681.12195.
    1. Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother. 2006;58:802–805. doi: 10.1093/jac/dkl311.
    1. Johnson DM, Fritsche TR, Sader HS, Jones RN. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents. 2006;27:557–560. doi: 10.1016/j.ijantimicag.2005.12.015.
    1. Lefort A, Pavie J, Garry L, Chau F, Fantin B. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob Agents Chemother. 2004;48:1061–1064. doi: 10.1128/AAC.48.3.1061-1064.2004.
    1. Baldoni D, Furustrand Tafin U, Aeppli S, et al. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. Int J Antimicrob Agents. 2013;42:220–225. doi: 10.1016/j.ijantimicag.2013.05.019.
    1. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis. 2005;40:374–380. doi: 10.1086/427283.
    1. Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis. 2013;13:252. doi: 10.1186/1471-2334-13-252.
    1. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407–1415. doi: 10.1086/497271.
    1. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004;44:689–695. doi: 10.1177/0091270004266620.
    1. Dunne MW, Zhou M, Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2015;45:393–398. doi: 10.1016/j.ijantimicag.2014.12.021.
    1. Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59:1849–1855. doi: 10.1128/AAC.04550-14.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj